PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10981253

Entacapone.

B S Chong·T L Mersfelder
View original source ↗Export metadata ↓

Abstract

OBJECTIVE: To introduce entacapone, a new catechol-O-methyltransferase inhibitor, and discuss its pharmacology, pharmacodynamics, pharmacokinetics, clinical efficacy, drug interactions, adverse events, dosage guidelines, and therapeutic and formulary considerations. DATA SOURCE: A MEDLINE database search (1966-December 1999) was performed to identify relevant English-language articles including recent studies, abstracts, and reviews. Search terms included entacapone, OR-611, catechol-O-methyltransferase inhibitor, and Parkinson's disease. STUDY SELECTION: Relevant published human studies were chosen to summarize the pharmacokinetics, clinical efficacy, adverse effects, and drug interactions. DATA EXTRACTION: All available human clinical trials were reviewed. DATA SYNTHESIS: Entacapone is the second medication of a new class of drugs, the catechol-O-methyltransferase inhibitors, indicated for clinical use as an adjunct to levodopa/carbidopa to treat patients with idiopathic Parkinson's disease who experience the signs and symptoms of end-of-dose wearing-off. Entacapone in combination with levodopa/dopa decarboxylase inhibitor has been shown to increase the AUC of levodopa, which leads to less fluctuation of levodopa plasma concentrations. Clinically, the duration of motor response to levodopa was prolonged as reflected by an increase in the mean on time. The addition of entacapone resulted in a decrease in the mean daily dosage of levodopa. The recommended dosage of entacapone is 200 mg administered orally with each dose of levodopa/carbidopa, up to a maximum of eight doses per day. Common adverse effects include dyskinesia, nausea, diarrhea, and urine discoloration. CONCLUSIONS: Entacapone should be considered as add-on treatment to levodopa/carbidopa in Parkinson's disease patients with end-of-dose wearing-off effect.

Explore related subjects

CatecholsClinical Trials as TopicDrug InteractionsEnzyme InhibitorsHumansNitrilesParkinson DiseaseRetrospective StudiesJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B S Chong, T L Mersfelder. 2000. Entacapone.. https://doi.org/10.1345/aph.19328

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Thermodynamics, kinetics, and mechanism of the reversible formation of oxorhenium(VII) catecholate complexes.

Mononuclear Re(V) compounds MeReO(mtp)NC(5)H(4)X, 3, where mtpH(2) is 2-(mercaptomethyl)thiophenol have been prepared from the monomerization of [MeReO(mtp)](2) by pyridines with electron-donating substituents in the para or meta position; X = 4-Me, 4-Bu(t), 3-Me, 4-Ph, and H. Analogous compounds, MeReO(edt)N(5)H(4)X, 4, edtH(2) = 1,2-ethanedithiol, were prepared similarly. The equilibrium constants for the reaction, dimer + 2Py = 2M-Py, are in the range (2.5-31.6) x 10(2) L mol(-1). Both groups of monomeric compounds react with quinones (phenanthrenequinone, PQ, and 3,5-tert-butyl-1,2-benzoquinone, DBQ), displacing the pyridine ligand and forming Re(VII) catecholate complexes MeReO(dithiolate)PCat and MeReO(dithiolate)DBCat. With PQ, the reaction MeReO(dithiolate)Py + PQ = MeReO(dithiolate)PCat + Py is an equilibrium; values of K(Q) for different Py ligands lie in the ranges 9.2-42.7 (mtp) and 3.2-11.2 (edt) at 298 K. These second-order rate constants (L mol(-1) s(-1)) at 25 degrees C in benzene were obtained for the PQ reactions: k(f) = (5.3-15.5) x 10(-2) (mtp), (6.6-16.4) x 10(-2) (edt); k(r) = (3.63-5.71) x 10(-3) (mtp), (14.7-22.0) x 10(-3) (edt). The ranges in each case refer to the series of pyridine ligands, the forward rate constant being the largest for C(5)H(5)N, with the lowest Lewis basicity. The reactions of MeReO(dithiolate)Py with DBQ proceed to completion. Values of k(f)/L mol(-1) s(-1) fall in a narrow range, 4.02 (X = Bu(t)) to 8.4 (X = H) with the dithiolate being mtp.

Catechols↗
PubMed2001

Extradiol oxidative cleavage of catechols by ferrous and ferric complexes of 1,4,7-triazacyclononane: insight into the mechanism of the extradiol catechol dioxygenases.

The major oxygenation product of catechol by dioxygen in the presence of FeCl(2) or FeCl(3), 1,4,7-triazacyclononane (TACN), and pyridine in methanol is the extradiol cleavage product 2-hydroxymuconic semi-aldehyde methyl ester (Lin, G.; Reid, G.; Bugg, T. D. H. J. Chem. Soc. Chem. Commun. 2000, 1119--1120). Under these conditions, extradiol cleavage of a range of 3- and 4-substituted catechols with electron-donating substituents is observed. The reaction shows a preference in selectivity and rate for iron(II) rather than iron(III) for the extradiol cleavage, which parallels the selectivity of the extradiol dioxygenase family. The reaction also shows a high selectivity for the macrocyclic ligand, TACN, over a range of other nitrogen- and oxygen-containing macrocycles. Reaction of anaerobically prepared iron-TACN complexes with dioxygen gave the same product as monitored by UV/vis spectroscopy. KO(2) is able to oxidize catechols with both electron-donating and electron-withdrawing substituents, implying a different mechanism for extradiol cleavage. Saturation kinetics were observed for catechols, which fit the Michaelis--Menten equation to give k(cat)(app) = 4.8 x 10(-3) s(-1) for 3-(2',3'-dihydroxyphenyl)propionic acid. The reaction was also found to proceed using monosodium catecholate in the absence of pyridine, but with different product ratios, giving insight into the acid/base chemistry of extradiol cleavage. In particular, extradiol cleavage in the presence of iron(II) shows a requirement for a proton donor, implying a role for an acidic group in the extradiol dioxygenase active site.

Catechols↗
PubMed2001

Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints.

Chromosomal breakage resulting from stabilization of DNA topoisomerase II covalent complexes by epipodophyllotoxins may play a role in the genesis of leukemia-associated MLL gene translocations. We investigated whether etoposide catechol and quinone metabolites can damage the MLL breakpoint cluster region in a DNA topoisomerase II-dependent manner like the parent drug and the nature of the damage. Cleavage of two DNA substrates containing the normal homologues of five MLL intron 6 translocation breakpoints was examined in vitro upon incubation with human DNA topoisomerase IIalpha, ATP, and either etoposide, etoposide catechol, or etoposide quinone. Many of the same cleavage sites were induced by etoposide and by its metabolites, but several unique sites were induced by the metabolites. There was a preference for G(-1) among the unique sites, which differs from the parent drug. Cleavage at most sites was greater and more heat-stable in the presence of the metabolites compared to etoposide. The MLL translocation breakpoints contained within the substrates were near strong and/or stable cleavage sites. The metabolites induced more cleavage than etoposide at the same sites within a 40 bp double-stranded oligonucleotide containing two of the translocation breakpoints, confirming the results at a subset of the sites. Cleavage assays using the same oligonucleotide substrate in which guanines at several positions were replaced with N7-deaza guanines indicated that the N7 position of guanine is important in metabolite-induced cleavage, possibly suggesting N7-guanine alkylation by etoposide quinone. Not only etoposide, but also its metabolites, enhance DNA topoisomerase II cleavage near MLL translocation breakpoints in in vitro assays. It is possible that etoposide metabolites may be relevant to translocations.

Catechols↗